Abstract
In November 2020, we conducted a cross sectional study to implement and test the method of acquaintance sampling (randomly sampling friends of randomly sampled individuals) in detecting students with higher probability of COVID-19 positivity. Overall, 879 students were randomly sampled and participated in this study. In an online survey, the randomly sampled participants nominated a friend, and reported their own and their nominated friend’s COVID-19 status. Nominated friends were about 1.64 (95% CI: 1.33, 2.00) times more likely to have ever been infected with COVID-19, compared to randomly sampled students. Our study corroborates the effectiveness of acquaintance sampling for identifying members of networks with higher COVID-19 risk. These findings could be useful for university policy makers when developing mitigation testing programs and intervention strategies against COVID-19 spread.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04620798
Clinical Protocols
https://ClinicalTrials.gov/show/NCT04620798
Funding Statement
Funding source for this study was IU FOUNDATION. The study was funded by donations from four private donors to the Indiana University Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Indiana University Office of Research Compliance approved the study protocol (protocol #2008293852).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos